SEC Info - Artemis Therapeutics, Inc. - ‘10-K’ for 12/31/20

SEC Info℠

Home

Help

Please Sign In

Artemis Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘EX-32.1’

On: Tuesday, 3/30/21, at 1:26pm ET · For: 12/31/20 · Accession #: 1178913-21-1229 · File #: 0-24431

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/21  Artemis Therapeutics, Inc.        10-K       12/31/20   42:2M                                     Z-K Global Ltd./FA

Annual Report — Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    317K 
 2: EX-31.1     Certification -- §302 - SOA'02 -- exhibit_31-1      HTML     17K 
 3: EX-32.1     Certification -- §906 - SOA'02 -- exhibit_32-1      HTML     14K 
10: R1          Document and Entity Information                     HTML     51K 
11: R2          Consolidated Balance Sheet                          HTML     72K 
12: R3          Consolidated Balance Sheet (Parenthetical)          HTML     33K 
13: R4          Consolidated Statement of Operation                 HTML     42K 
14: R5          Consolidated Statements of changes of               HTML     35K 
                shareholder's equity (Deficiency)                                
15: R6          Consolidated Statement of Cash Flows                HTML     45K 
16: R7          General                                             HTML     22K 
17: R8          Significant Accounting Policies                     HTML     27K 
18: R9          Commitments and Contingencies                       HTML     17K 
19: R10         Income Tax                                          HTML     42K 
20: R11         Warrants Issued to Investors                        HTML     19K 
21: R12         Computation of Net Loss per Share                   HTML     29K 
22: R13         Stock Capital                                       HTML     57K 
23: R14         Related Parties                                     HTML     17K 
24: R15         Subsequent Events                                   HTML     16K 
25: R16         Significant Accounting Policies (Policies)          HTML     49K 
26: R17         Income Tax (Tables)                                 HTML     38K 
27: R18         Warrants Issued to Investors (Tables)               HTML     20K 
28: R19         Computation of Net Loss per Share (Tables)          HTML     28K 
29: R20         Stock Capital (Tables)                              HTML     53K 
30: R21         Commitments and Contingencies (Details)             HTML     18K 
31: R22         Income Tax (Narrative) (Details)                    HTML     21K 
32: R23         Income Tax (Schedule of Deferred Income Taxes)      HTML     19K 
                (Details)                                                        
33: R24         Income Tax (Schedule of Net Operating Loss          HTML     18K 
                Carryforwards) (Details)                                         
34: R25         Warrants Issued to Investors (Details)              HTML     19K 
35: R26         Computation of Net Loss per Share (Schedule of      HTML     35K 
                Calculation of Basic Loss Per Share) (Details)                   
36: R27         Stock Capital (Narrative) (Details)                 HTML     42K 
37: R28         Stock Capital (Summary of Stock Option Activity)    HTML     41K 
                (Details)                                                        
38: R29         Stock Capital (Summary of Stock Option Exercise     HTML     30K 
                price) (Details)                                                 
39: R30         Related Parties (Narrative) (Details)               HTML     23K 
41: XML         IDEA XML File -- Filing Summary                      XML     71K 
40: EXCEL       IDEA Workbook of Financial Reports                  XLSX     40K 
 4: EX-101.INS  XBRL Instance -- atms-20201231                       XML    488K 
 6: EX-101.CAL  XBRL Calculations -- atms-20201231_cal               XML     70K 
 7: EX-101.DEF  XBRL Definitions -- atms-20201231_def                XML    211K 
 8: EX-101.LAB  XBRL Labels -- atms-20201231_lab                     XML    433K 
 9: EX-101.PRE  XBRL Presentations -- atms-20201231_pre              XML    325K 
 5: EX-101.SCH  XBRL Schema -- atms-20201231                         XSD     82K 
42: ZIP         XBRL Zipped Folder -- 0001178913-21-001229-xbrl      Zip     57K

‘EX-32.1’ — Certification — §906 – SOA’02 — exhibit_32-1

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EXHIBIT 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

In connection with the Annual Report of Artemis Therapeutics, Inc., a Delaware corporation (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer does hereby certify, that to the best of the officer’s knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 30, 2021	/s/ *Chanan Morris*
	By: *Chanan Morris, Chief Financial Officer* (Principal Executive Officer and Principal Financial Officer)

Dates Referenced Herein

This ‘10-K’ Filing	Date	Other Filings

Filed on:	3/30/21	None on these Dates
For Period end:	12/31/20
		List all Filings

7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/19/19  Manuka, Inc.                      10-Q        6/30/19   43:2.4M                                   Z-K Global Ltd./FA
10/25/17  Manuka, Inc.                      8-K:1,3,5,910/25/17    4:558K                                   Z-K Global Ltd./FA
 8/29/16  Manuka, Inc.                      8-K:1,2,3,5 8/29/16    5:1M                                     Z-K Global Ltd./FA
 8/09/11  Artemis Therapeutics, Inc.        DEF 14A     8/09/11    1:626K                                   Z-K Global Ltd./FA
 9/24/10  Artemis Therapeutics, Inc.        8-K:5,9     9/24/10    5:52K                                    Z-K Global Ltd./FA
 4/04/08  Artemis Therapeutics, Inc.        8-K:5,9     4/04/08    2:5K                                     Z-K Global Ltd./FA
11/14/02  Artemis Therapeutics, Inc.        10QSB       9/30/02    6:113K                                   Bowne & C… Smartedgar/FA

↑Top

Filing Submission 0001178913-21-001229 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)